This in vitro study allowed us to select a lead candidate among a series of peptide variants derived from the neutrophil granule protein cathepsin G. Our lead candidate CG D/R, E/R is a multitarget peptide that is expected to have synergistic effects on the cognitive decline associated with Alzheimer’s disease. This evidence concerns the gene CTSG and early-onset autosomal dominant Alzheimer disease.